Website
News25/Ratings12
News · 26 weeks41+200%
2025-10-262026-04-19
Mix3290d
- SEC Filings14(44%)
- Other9(28%)
- Insider3(9%)
- Analyst3(9%)
- Offering2(6%)
- Leadership1(3%)
Latest news
25 items- SECImmunic Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic, Inc. Announces 1-for-10 Reverse Stock SplitNEW YORK, April 23, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026.Immunic's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "IMUX" and will begin trading on a reverse stock split-adjusted basis at the opening of the Nasdaq Capital Market on April 27, 2026. The new CUSIP number for the split-adjusted common stock will be 4525EP200.At the Company's special me
- SECAmendment: SEC Form 10-K/A filed by Immunic Inc.10-K/A - IMMUNIC, INC. (0001280776) (Filer)
- ANALYSTStifel initiated coverage on Immunic with a new price targetStifel initiated coverage of Immunic with a rating of Buy and set a new price target of $2.50
- ANALYSTImmunic downgraded by D. Boral CapitalD. Boral Capital downgraded Immunic from Buy to Hold
- SECImmunic Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events8-K - IMMUNIC, INC. (0001280776) (Filer)
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- SECSEC Form S-8 filed by Immunic Inc.S-8 - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Participate in Scientific and Medical Conferences in AprilNEW YORK, April 9, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following scientific and medical conferences in April:April 14-16: 8th Annual Neuroimmunology Drug Development Summit. Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will give a presentation highlighting lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), at this conference in Boston. The presentation will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
- SECSEC Form S-3 filed by Immunic Inc.S-3 - IMMUNIC, INC. (0001280776) (Filer)
- SECImmunic Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic Regains Compliance with Nasdaq Minimum Bid Price RequirementNEW YORK, April 1, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that it received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on March 27, 2026, informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.According to the Notice, Immunic has regained compliance with the minimum bid price requirement, because the closing bid price of the Company's common stock was at $1.00 pe
- INSIDERSEC Form 3 filed by new insider Congleton Jon3 - IMMUNIC, INC. (0001280776) (Issuer)
- SECImmunic Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton– Nearly 40-Year Biopharmaceutical Professional with Deep CNS and Commercial Leadership Experience in Multiple Sclerosis –– Served on Original Team Responsible for the Launch of Copaxone® in the United States –NEW YORK, March 31, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to its Board of Directors, effective March 27, 2026.Mr. Congleton has a strong track record of building and leadin
- ANALYSTGuggenheim initiated coverage on Immunic with a new price targetGuggenheim initiated coverage of Immunic with a rating of Buy and set a new price target of $7.00
- PRImmunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium– Patent Covers Label-Mandated Dosing Scheme Across All Indications, Including Multiple Sclerosis; Previously Granted by the USPTO in 2023 –– Broad Protection Extends to All Forms of Vidofludimus, Including Its Salts, Solvates and Free Acid –– Multi-Layered Intellectual Property Strategy Expected to Provide Protection at Least Into 2041 in the United States and Into 2039 in Europe –NEW YORK, March 10, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced that the European Patent Office (EPO) has granted a key European patent, EP3713554, directed to l
- SECSEC Form D filed by Immunic Inc.D - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic to Participate in Investor Conferences in MarchNEW YORK, March 3, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced participation in the following investor conferences in March:March 8-11: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, and Jason Tardio, President and Chief Operating Officer of Immunic, will participate in a fireside chat on Wednesday, March 11, at 10:40 am ET at this conference in Miami. A webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentat
- SECSEC Form DEF 14A filed by Immunic Inc.DEF 14A - IMMUNIC, INC. (0001280776) (Filer)
- INSIDERNew insider Bvf Partners L P/Il claimed ownership of 7,590,690 shares (SEC Form 3)3 - IMMUNIC, INC. (0001280776) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nagel Robert Thorvald3 - IMMUNIC, INC. (0001280776) (Issuer)
- SECSEC Form 10-K filed by Immunic Inc.10-K - IMMUNIC, INC. (0001280776) (Filer)
- SECImmunic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - IMMUNIC, INC. (0001280776) (Filer)
- PRImmunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update– Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 –– Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million –– Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization –NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results